Utama › Penyakit Graft-versus-host › Pennsylvania
Kajian klinikal Penyakit Graft-versus-host di Pennsylvania
6 kajian untuk Penyakit Graft-versus-host sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
- UMPC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT07565220A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 2
Umur 2 ke atas · Semua jantina · Dikemas kini 16 Jun 2026 · NCT04710576A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
- University of Pittsburgh Medical Center (Data Collection Only), Pittsburgh
Mengambil pesertaFasa 2
Umur 4 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT05675930A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Mei 2026 · NCT06615050Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
- Penn State Cancer Institute, Hershey
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Apr 2026 · NCT06926595A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Dis 2025 · NCT06619561Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.